COMMUNIQUÉS West-GlobeNewswire

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 juillet 2026
28/08/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
OSE Immunotherapeutics organisera un webcast dédié à lusvertikimab avec des leaders d’opinion le 2 septembre 2026
28/08/2026
NANTES, France, le 28 août 2026, 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) (la « Société ») , annonce aujourd’hui que la Société organisera un webcast avec des experts internationaux des [...]
OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
28/08/2026
NANTES, France, August 28, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company") , today announced that the Company will host a webcast with international experts in Inflammatory [...]
EssilorLuxottica annonce le lancement d’un programme de rachat d’actions
28/08/2026
EssilorLuxottica annonce le lancement d’un programme de rachat d’actions Paris, France (28 août 2026 – 8h00) – EssilorLuxottica annonce le lancement d’un programme de rachat d’actions qui traduit la confiance du Groupe [...]
EssilorLuxottica announces the launch of a share buyback program
28/08/2026
EssilorLuxottica announces the launch of a share buyback program Paris, France (August 28, 2026 – 8:00am) – EssilorLuxottica announces the launch of a share buyback program, reflecting the Group’s confidence in its [...]
Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
28/08/2026
FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate [...]
Chiesi Global Rare Diseases Demonstrates Its Ongoing Commitment to the Rare Disease Community at the Society of Inborn Errors of Metabolism (SSIEM) 2026 Annual Symposium
28/08/2026
-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research reflects Chiesi’s [...]
Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)
28/08/2026
The SALWEEN study showed significant improvements in vision and retinal health 1 More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed [...]
Chiesi Global Rare Diseases Demonstrates Its Ongoing Commitment to the Rare Disease Community at the Society of Inborn Errors of Metabolism (SSIEM) 2026 Annual Symposium
28/08/2026
-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research reflects Chiesi’s [...]
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
28/08/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that new solid forms and alternative crystal structures of its [...]
Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
28/08/2026
ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCM Supplemental New [...]
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
28/08/2026
ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Immuron Reports FY26 Preliminary Results
28/08/2026
MELBOURNE, Australia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026. Results exceed expectations In [...]
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
28/08/2026
BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 [...]
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
28/08/2026
Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participants Achieved the [...]
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
28/08/2026
BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. [...]
Avricore Grants Options
28/08/2026
VANCOUVER, British Columbia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) today announces that the Company’s board of directors has approved the granting of stock options (the “Options”) [...]
XORTX Announces Termination and Postponement of Investor Relations Program
28/08/2026
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]
Oxford Treatment Center’s Medical Director, Dr. Lucas Trautman, Named a 2026 Health Care Hero by Memphis Business Journal
28/08/2026
ETTA, Miss., Aug. 27, 2026 (GLOBE NEWSWIRE) -- For more than two decades, Dr. Lucas Trautman, M.D., MPH, ABPN, ABPM , has served patients in Memphis and across the Mid-South through his work in psychiatry and addiction [...]

Pages